Brief: BioArctic Says New Drug Application For Subcutaneous Formulation Of Leqembi Submitted In Japan
28/11/2025 05:31
Nov 28 (Reuters) - BioArctic AB BIOAb.ST: NEW DRUG APPLICATION FOR SUBCUTANEOUS FORMULATION OF LEQEMBI[®] SUBMITTED IN JAPAN BIOARCTIC AB - SIMILAR APPLICATION FOR SUBCUTANEOUS LECANEMAB SUBMITTED TO U.S. FDA Source text: ID:nWkr6cl6B6 Further company coverage: [BIOAb.ST] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB
See all newsBrief: BioArctic And Lilly Sign Research, Collaboration Agreement
Brief: Bioarctic AB Declares Dividend Of Sek 2 Per Share With 1 June 2026 Record Date
Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties
Brief: BioArctic Q1 Operating Profit SEK 210.8 Million